Toggle Side Panel

NICE consulting on use of elacestrant for advanced breast cancer

max
MariaPCC 3 October 2024

The National Institute for Health and Care Excellence (NICE) is consulting on draft guidance that does not recommend elacestrant for treating a type of advanced breast cancer. The draft guidance, which is open for public consultation until 22 October, does not recommend elacestrant for treating oestrogen receptor-positive, human epidermal growth factor receptor 2-negative (HER2-), locally advanced or metastatic breast cancer with an activating ESR1 mutation.

Categories: News

Report

Block Member?

Please confirm you want to block this member.

You will no longer be able to:

  • See blocked member's posts
  • Mention this member in posts
  • Invite this member to groups
  • Message this member
  • Add this member as a connection

Please note: This action will also remove this member from your connections and send a report to the site admin. Please allow a few minutes for this process to complete.

Report

You have already reported this .
Keep up to date

Sign up to receive our daily news alerts straight to your inbox. Subscribe to our weekly newsletter containing a summary of the week’s news, blog and vote on our poll.

Weekly Newsletter

Daily news updates

Have a discussion

Help keep the conversation going between meetings by creating a forum to hold discussions with your members. It’s an easy way to manage and communicate with members.

Create a network

Create a network to share documents, knowledge and best practice with your colleagues. Set up a network to keep in touch with other people in your organisation or with shared interest groups across organisational boundaries.

Networks can be open to all or available only to a closed group defined by the administrator.

Join or create a network here.